Pfizer is in superior talks to purchase World Blood Therapeutics the maker of a lately accepted drug for sickle-cell illness, for about $5 billion, within the newest transfer by the drug large to bolster its portfolio and pipeline.
Pfizer is aiming to seal a deal for GBT within the coming days, in line with folks acquainted with the matter. The scenario remains to be fluid, and different suitors are nonetheless within the combine, a few of the folks stated. GBT broadcasts its second-quarter outcomes Monday.
